Impaired resolution of inflammation in human chronic heart failure
- 28 March 2014
- journal article
- research article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 44 (6) , 527-538
Abstract
Background: Lipoxins (LXs) are proresolving and anti‐inflammatory eicosanoids whose role in chronic heart failure (CHF) pathogenesis has never been investigated. This study evaluated levels of LXs in CHF patients, its relationship with disease severity and correlation with established CHF biomarkers. The effect of low‐dose aspirin [acetylsalicylic acid (ASA)] on the levels of LXs was also studied.Materials and methods: Lipoxin A4 (LXA4), 15‐epi‐lipoxin A4 (15‐epi‐LXA4) and myeloperoxidase (MPO) concentration and activity were evaluated by immunoenzymatic and spectrophotometric assays in 34 CHF patients [New York Heart Association (NYHA) functional class I to IV]. B‐type natriuretic peptide (BNP), troponin, myoglobin, C‐reactive protein (CRP) and uric acid (UA) were also analyzed.Results: Patients were stratified into mild‐to‐moderate CHF (NYHA, classes I and II) and severe CHF (NYHA classes III and IV). Severe patients had lower plasma LXA4 (0·262 ± 0·034 vs. 0·362 ± 0·039 ng/mL, P < 0·05) and decreased urinary 15‐epi‐LXA4 levels (2·28 ± 0·44 vs. 4·88 ± 1·03 μg/day, P < 0·05) besides exhibiting increased plasma BNP (1464 ± 442 vs. 555 ± 162 pg/mL, P < 0·05) and MPO activity (45·15 ± 11·56 vs. 15·90 ± 2·80 μmol/min/mg protein, P < 0·05). Plasma LXA4 was inversely correlated with BNP, troponin, myoglobin, CRP, UA and MPO activity. ASA treatment was associated with higher urinary excretion of 15‐epi‐LXA4 (7·70 ± 1·48 vs. 2·06 ± 0·30 μg/day, P < 0·05) in mild‐to‐moderate CHF patients and lower BNP levels in both groups.Conclusions: Higher severity of CHF is associated with reduced levels of LXs. Plasma LXA4 appears to be a valuable marker for risk stratification in CHF. Furthermore, the ASA‐related increase in urinary 15‐epi‐LXA4 suggests enhanced renal synthesis of this eicosanoid and may represent a disregarded benefit of ASA.Keywords
This publication has 39 references indexed in Scilit:
- Regulation of the Inflammatory Response in Cardiac RepairCirculation Research, 2012
- Indirect calibration between clinical observers - application to the New York Heart Association functional classification systemBMC Research Notes, 2011
- Aspirin-Triggered Lipoxin and Resolvin E1 Modulate Vascular Smooth Muscle Phenotype and Correlate with Peripheral AtherosclerosisThe American Journal of Pathology, 2010
- Myeloperoxidase acts as a profibrotic mediator of atrial fibrillationNature Medicine, 2010
- A catalogue of reporting guidelines for health researchEuropean Journal of Clinical Investigation, 2009
- Lipoxins: resolutionary roadBritish Journal of Pharmacology, 2009
- Resolution of in flammation: state of the art, definitions and termsThe FASEB Journal, 2007
- Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failureHeart, 2006
- Lipoxin biosynthesis in inflammatory bowel diseaseProstaglandins & Other Lipid Mediators, 2006
- Lipoxins: Potential anti-inflammatory, proresolution, and antifibrotic mediators in renal diseaseKidney International, 2004